GO
Loading...

Boston Scientific Corp

More

  • April 15- U.S. health regulators have approved four Boston Scientific Corp implantable devices for heart patients, including a next generation of smaller defibrillators to treat abnormal heart rhythms, the company said on Tuesday.

  • Final Glance: Medical Devices companies Monday, 14 Apr 2014 | 6:01 PM ET

    Allergan rose $3.08 or 2.5 percent, to $123.97. Baxter International Inc. rose$. 78 or 1.1 percent, to $72.76. Boston Scientific Corp. rose$. 62 or 4.9 percent, to $13.31.

  • Midday Glance: Medical Devices companies Monday, 14 Apr 2014 | 2:08 PM ET

    Allergan rose $3.06 or 2.5 percent, to $123.95. Baxter International Inc. rose$. 79 or 1.1 percent, to $72.77. Boston Scientific Corp. rose$. 51 or 4.0 percent, to $13.20.

  • Early Glance: Medical Devices companies Monday, 14 Apr 2014 | 10:21 AM ET

    Allergan rose$. 47 or. 4 percent, to $121.36. Baxter International Inc. rose$. 47 or. 7 percent, to $72.45. Boston Scientific Corp. rose$. 48 or 3.8 percent, to $13.17.

  • Final Glance: Medical Devices companies Friday, 11 Apr 2014 | 6:03 PM ET

    Allergan rose $4.26 or 3.7 percent, to $120.89. Baxter International Inc. fell$. 28 or. 4 percent, to $71.98. Boston Scientific Corp. fell$. 24 or 1.9 percent, to $12.69.

  • Midday Glance: Medical Devices companies Friday, 11 Apr 2014 | 1:51 PM ET

    Allergan rose $4.38 or 3.8 percent, to $121.00. Baxter International Inc. rose$. 15 or. 2 percent, to $72.41. Boston Scientific Corp. fell$. 32 or 2.4 percent, to $12.62.

  • Early Glance: Medical Devices companies Thursday, 10 Apr 2014 | 10:24 AM ET

    Allergan fell $1.17 or 1.0 percent, to $119.74. Baxter International Inc. fell$. 37 or. 5 percent, to $73.08. Boston Scientific Corp. fell$. 18 or 1.3 percent, to $13.36.

  • Final Glance: Medical Devices companies Wednesday, 9 Apr 2014 | 6:06 PM ET

    Allergan rose $3.00 or 2.5 percent, to $120.91. Baxter International Inc. rose $1.15 or 1.6 percent, to $73.45. Boston Scientific Corp. rose$. 63 or 4.9 percent, to $13.54.

  • Wall Street analysts had estimated a potential market of $3 billion for the devices made by Medtronic Inc, Boston Scientific Corp and St Jude Medical Inc. But failure of the high-stakes clinical trial set off a heated debate between doctors who believe the approach is worth saving and those who say results show it provides no clear benefit.

  • Midday Glance: Medical Devices companies Wednesday, 9 Apr 2014 | 1:15 PM ET

    Allergan rose $1.95 or 1.7 percent, to $119.86. Baxter International Inc. rose$. 62 or. 9 percent, to $72.92. Boston Scientific Corp. rose$. 47 or 3.6 percent, to $13.38.

  • US stocks rally on Fed minutes, earnings news Wednesday, 9 Apr 2014 | 9:16 AM ET

    NEW YORK— Once again, it was the Federal Reserve to the rescue for the stock market. Facebook rose the most in the S&P 500, jumping 7.3 percent, followed closely by biotech company Vertex Pharmaceuticals, up 7 percent.

  • Early Glance: Medical Devices companies Tuesday, 8 Apr 2014 | 10:43 AM ET

    Allergan fell$. 65 or. 5 percent, to $120.13. Baxter International Inc. rose$. 24 or. 3 percent, to $72.73. Boston Scientific Corp. fell$. 17 or 1.3 percent, to $13.05.

  • Final Glance: Medical Devices companies Monday, 7 Apr 2014 | 6:01 PM ET

    Allergan fell $3.35 or 2.7 percent, to $120.77. Baxter International Inc. fell$. 44 or. 6 percent, to $72.49. Boston Scientific Corp. fell$. 28 or 2.1 percent, to $13.22.

  • Midday Glance: Medical Devices companies Monday, 7 Apr 2014 | 1:50 PM ET

    Allergan fell $3.31 or 2.7 percent, to $120.81. Baxter International Inc. rose$. 06 or. 1 percent, to $72.99. Boston Scientific Corp. fell$. 15 or 1.1 percent, to $13.35.

  • Final Glance: Medical Devices companies Friday, 4 Apr 2014 | 6:19 PM ET

    Allergan fell $1.26 or 1.0 percent, to $124.12. Baxter International Inc. fell$. 46 or. 6 percent, to $72.93. Boston Scientific Corp. fell$. 27 or 2.0 percent, to $13.50.

  • Midday Glance: Medical Devices companies Friday, 4 Apr 2014 | 1:20 PM ET

    Allergan fell$. 24 or. 2 percent, to $125.14. Baxter International Inc. rose$. 26 or. 3 percent, to $73.64. Boston Scientific Corp. fell$. 21 or 1.5 percent, to $13.57.

  • Early Glance: Medical Devices companies Friday, 4 Apr 2014 | 10:57 AM ET

    Allergan rose$. 66 or. 5 percent, to $126.04. Baxter International Inc. rose$. 24 or. 3 percent, to $73.63. Boston Scientific Corp. rose$. 08 or. 6 percent, to $13.85.

  • Feb 18- Medtronic Inc on Tuesday reported a lower quarterly net profit after it took charges for an experimental blood pressure device that failed to prove effective in a clinical study. Medtronic shares fell 2.3 percent to $55.56 in morning trading on the New York Stock Exchange.

  • Feb 18- Medtronic Inc on Tuesday reported lower quarterly net earnings due to charges for the failed clinical study of a treatment being developed for high blood pressure. Excluding the charges and other one-time items, Medtronic earned 91 cents a share, in line with the analysts' average estimate, according to Thomson Reuters I/B/E/S.

  • Feb 4- Medtronic Inc's stumble in its U.S. medical device study to treat high blood pressure could create an opportunity for other device makers to pick up where their rival has left off, Boston Scientific Corp Chief Executive Mike Mahoney said on Tuesday.

Most Popular Video

Wednesday, 16 Apr 2014 | 4:40 AM ET

Loyalists around the world have embraced it as the cryptocurrency of the future, but some big names on the street differ widely in their beliefs about bitcoin. The Oracle of Omaha thinks it's a "joke." Tech entrepreneur Marc Andreessen counters that Buffett is out of touch, while bitcoin believers like Jonathan Rumion fully embrace the digital currency by buying groceries with bitcoin and even getting paid in bitcoin. CNBC's Mary Thompson reports.

Wednesday, 16 Apr 2014 | 3:00 AM ET

European shares opened higher on Wednesday as better-than-expected Chinese growth data buoyed sentiment.

Wednesday, 16 Apr 2014 | 2:00 AM ET

Brady Dougan, CEO of Credit Suisse, says the bank's fixed income business is "strong", while the investment banking arm has performed well.